Takeda Pharmaceutical Co Ltd ADR Total Liabilities
Takeda Pharmaceutical Co Ltd ADR total liabilities. Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) has total liabilities worth $7.77 Trillion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Takeda Pharmaceutical Co Ltd ADR liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Takeda Pharmaceutical Co Ltd ADR (2001–2025)
Total liabilities of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025. This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. Explore TAK long-term investment intensity to see how much of total assets are deployed in long-term investments.
Takeda Pharmaceutical Co Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Takeda Pharmaceutical Co Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elite Material Co Ltd
TW:2383
|
Taiwan | NT$100.27 Billion |
|
Delta Air Lines Inc
NYSE:DAL
|
USA | $64.51 Billion |
|
Vale S.A
MX:VALEN
|
Mexico | MX$50.33 Billion |
|
Target Corporation
NYSE:TGT
|
USA | $44.49 Billion |
|
Diamondback Energy Inc
NASDAQ:FANG
|
USA | $28.09 Billion |
|
Garmin Ltd
NYSE:GRMN
|
USA | $2.39 Billion |
|
Société Générale Société anonyme
F:SGE1
|
Germany | €1.59 Trillion |
|
VOLVO B (FRIA) UNSP.ADR
F:VOL4
|
Germany | €491.70 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Takeda Pharmaceutical Co Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Takeda Pharmaceutical Co Ltd ADR.
Liquidity & Leverage Metrics
Takeda Pharmaceutical Co Ltd ADR Total Liabilities Ratios Explained
Takeda Pharmaceutical Co Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Takeda Pharmaceutical Co Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Takeda Pharmaceutical Co Ltd ADR (2001–2025)
The table below shows the annual total liabilities of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $7.31 Trillion | -6.67% |
| 2024-03-31 | $7.83 Trillion | +3.05% |
| 2023-03-31 | $7.60 Trillion | +1.45% |
| 2022-03-31 | $7.49 Trillion | -3.11% |
| 2021-03-31 | $7.74 Trillion | -4.43% |
| 2020-03-31 | $8.09 Trillion | -7.06% |
| 2019-03-31 | $8.71 Trillion | +316.87% |
| 2018-03-31 | $2.09 Trillion | -13.20% |
| 2017-03-31 | $2.41 Trillion | +32.76% |
| 2016-03-31 | $1.81 Trillion | -13.26% |
| 2015-03-31 | $2.09 Trillion | +3.03% |
| 2014-03-31 | $2.03 Trillion | +17.10% |
| 2013-03-31 | $1.73 Trillion | +15.09% |
| 2012-03-31 | $1.51 Trillion | +131.65% |
| 2011-03-31 | $649.75 Billion | -1.33% |
| 2010-03-31 | $658.53 Billion | -6.77% |
| 2009-03-31 | $706.35 Billion | +34.10% |
| 2008-03-31 | $526.75 Billion | -13.84% |
| 2007-03-31 | $611.38 Billion | -11.89% |
| 2006-03-31 | $693.87 Billion | +27.54% |
| 2005-03-31 | $544.02 Billion | -1.92% |
| 2004-03-31 | $554.65 Billion | +12.82% |
| 2003-03-31 | $491.64 Billion | -2.82% |
| 2002-03-31 | $505.88 Billion | +1.65% |
| 2001-03-31 | $497.69 Billion | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more